Eversept Partners, LP Arbutus Biopharma Corp Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $765,335 - $1.2 Million	-97,495 Closed	0 $0
Q2 2018 Nov 08, 2023	SELL	$5.0 - $7.35 $100,000 - $147,000	-20,000 Reduced 17.02%	97,495 $711,000
Q2 2018 Aug 14, 2018	SELL	$5.0 - $7.35 $100,000 - $147,000	-20,000 Reduced 17.02%	97,495 $712,000
Q1 2018 Nov 08, 2023	BUY	$4.4 - $6.05 $516,978 - $710,844	117,495 New	117,495 $587 Million
Q1 2018 May 14, 2018	BUY	$4.4 - $6.05 $44,000 - $60,500	10,000 Added 9.3%	117,495 $587,000

Q4 2017 Nov 08, 2023	BUY	$4.45 - $7.7 $478,352 - $827,711	107,495 New	107,495 $543 Million
Q4 2017 Feb 12, 2018	BUY	$4.45 - $7.7 $478,352 - $827,711	107,495	107,495 $543,000

194

118M

2.67M

693K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $678M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.